206 results about "Exovesicles" patented technology

Disclosed are methods of treating traumatic brain injury in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

Disclosed are methods of treating infertility or increasing fertility of a female subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention provides a method for separating extracellular vesicles from a milk source, which comprises the step of adding a dispersing agent before adding a precipitator into the milk source to precipitate casein so as to reduce the wrapping of protein precipitation on the extracellular vesicles and improve the yield of the extracellular vesicles, thereby obtaining a milk source extract rich in the extracellular vesicles.

The invention provides a rapid quantitative analysis method for an outer vesicle proteome, and belongs to the technical field of quantitative analysis of the outer vesicle proteome. According to the rapid quantitative analysis method for the outer vesicle proteome, firstly, a high-quality outer vesicle sample is obtained through low-speed centrifugation, ultra-speed centrifugation and membrane filtration; and obtaining proteome data by utilizing two-dimensional electrophoresis and mass spectrometry. Then, a mathematical model equation set is constructed for preliminary analysis, a protein interaction network is optimized through an embedded game optimization index model, and feature extraction and quantitative analysis are conducted through a convolution parameter adaptive function and a residual network deep learning model; finally, a quantitative analysis result containing the protein expression level and the function importance is generated in combination with the multi-dimensional protein expression contribution index, and the technical problem that in the prior art, in the rapid quantitative analysis process of the outer vesicle proteome, the protein component complexity is high, and consequently the quantitative precision is low is solved.

The invention discloses a preparation method of artemisia apiacea extracellular vesicles, which comprises the following steps: step 1, pre-treating artemisia apiacea, carrying out primary centrifugal treatment, removing large plant tissues and cell debris, carrying out secondary centrifugal treatment, filtering by a needle filter, and collecting; step 2, transferring the filtered suspension to a sucrose density gradient solution, then carrying out third centrifugal treatment, collecting the solution with the concentration of 30% in the layer, and carrying out fourth centrifugal treatment to obtain artemisia apiacea extracellular vesicles; the invention further discloses an artemisia apiacea extracellular vesicle, a pharmaceutical composition for treating cerebral apoplexy, a medicine and application of the artemisia apiacea extracellular vesicle in preparation of the medicine for treating cerebral apoplexy. The naturally-sourced vesicle delivery system provided by the invention is expected to have higher safety and lower toxic and side effects, and the enrichment concentration of the therapeutic component at the focus part of cerebral apoplexy is improved, so that the bioavailability and the treatment efficiency of the medicine are remarkably improved.

The invention relates to the technical field of biological medicine, in particular to a lactobacillus-sourced extracellular vesicle and application of the lactobacillus-sourced extracellular vesicle in prevention and treatment of necrotizing enterocolitis, the extracellular vesicle is prepared from lactobacillus, the lactobacillus is Lactobacillus rhamnosus GG, the strain is purchased in the American Center for Type Culture Collection, and the preservation number is ATCC 53103. The preparation method of the extracellular vesicles comprises the following steps: carrying out ultracentrifugation on a lactobacillus culture solution, removing thalli, then collecting supernate, carrying out primary microfiltration, taking micro-filtrate, carrying out differential centrifugation, resuspending precipitates by using PBS, then carrying out secondary microfiltration, collecting the micro-filtrate, carrying out density gradient centrifugation, and collecting a 30-45% interface vesicle layer. The invention discloses a synergistic effect mode between intestinal symbiotic flora and intestinal epithelial cell metabolic molecules for the first time, and the discovery is expected to construct a brand-new mechanism normal form for regulating the host intestinal barrier function by flora.

Disclosed are methods of treating Ehlers-Danlos Syndrome in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.

The invention discloses a kit for detecting miRNAs of multiple extracellular vesicles based on a TtAgo-driven rolling circle amplification technology and application of the kit, a platform combines TtAgo protein and RCA reaction, cooperates with endonuclease activity and DNA polymerase activity of TtAgo, accurately controls reaction kinetic balance between temperature and enzyme activity, not only does not damage the cutting activity of TtAgo, but also can detect miRNAs of multiple extracellular vesicles. The method provided by the invention can be used for detecting multiple extracellular vesicles miRNAs, ensures strong polymerization amplification performance, creates a strong one-step single-tube experiment, greatly simplifies the experimental process, shortens the detection time, realizes ultra-sensitive and specific detection of nucleic acid markers, and can be used for detecting multiple extracellular vesicles miRNAs.

The invention provides a preparation method of high-purity extracellular vesicles, and belongs to the technical field of extracellular vesicles, and the preparation method comprises the following steps: collecting cell culture supernatant generated by culturing cells, and setting a process parameter combination based on an orthogonal test principle; centrifuging the cell culture supernate for the first time; carrying out secondary centrifugation on the first centrifugal supernatant; filtering and purifying the first extracellular vesicles to obtain second extracellular vesicles; purifying the second extracellular vesicle to obtain a third extracellular vesicle; concentrating the third extracellular vesicles to obtain fourth extracellular vesicles; performing characteristic detection on the fourth extracellular vesicles, and recording detection data; establishing a preparation process physical and chemical model; performing parameter fitting on the preparation process physical and chemical model to obtain an optimal process parameter combination; carrying out an extracellular vesicle preparation experiment by adopting the optimal process parameter combination, and correcting a preparation process physical and chemical model to obtain a final process parameter combination; and preparing the extracellular vesicles.

The invention belongs to the technical field of biological medicine, and particularly relates to an extracellular vesicle drug delivery system, a preparation method thereof and application of the extracellular vesicle drug delivery system in treatment of Alzheimer's disease. According to the invention, one or more of stilbene glucoside, emodin, kaempferol, resveratrol and quercetin are used for regulating and controlling the expression of miRNA (micro Ribonucleic Acid) related to the disease progress in the extracellular vesicles, and the result shows that one or more of miR-let-7c-5p, miR-486-5p, miR-132-3p, miR-160b and miR-129-5p is remarkably up-regulated, and one or more of miR-342-3p, miR-16-5p and miR-125b-5p is remarkably down-regulated. The regulated extracellular vesicles can be used for treating Alzheimer's disease, relieving Tau protein abnormal phosphorylation, reducing amyloid protein beta deposition, inhibiting microglial cell activation, protecting neuronal cells and relieving memory deficits.

The invention discloses application of pseudo-ginseng external vesicles in preparation of drugs for preventing and treating or improving heart diseases. The plant exovesicle provided by the invention has the advantages of low toxicity, high biocompatibility, biodegradability, no induction of immunogenicity, high yield and large-scale preparation. A large number of experimental studies prove that the pseudo-ginseng external vesicles disclosed by the invention have a remarkable heart disease prevention and treatment effect. Therefore, development and application of the fresh pseudo-ginseng medicine are promoted.

The invention discloses a lactobacillus paracasei extracellular vesicle for relieving ulcerative colitis and application of the lactobacillus paracasei extracellular vesicle, and belongs to the technical field of microbial extracellular vesicles. The invention provides a strain of Lactobacillus paracasei Li-1, and the preservation number of the Lactobacillus paracasei Li-1 is CCTCC (China Center For Type Culture Collection) NO: M 2025435. The invention further provides the extracellular vesicles of the lactobacillus paracasei Li-1, and the extracellular vesicles are extracted from fermentation liquor of the lactobacillus paracasei Li-1. The application of the Lactobacillus paracasei extracellular vesicles in relieving and / or treating ulcerative colitis shows that the Lactobacillus paracasei extracellular vesicles significantly improve the weight change rate, DAI index and colon length of mice, and intervene the progress of ulcerative colitis. The lactobacillus paracasei extracellular vesicles can relieve ulcerative colitis, and a theoretical basis is provided for developing the lactobacillus paracasei extracellular vesicles into microecologics to be applied to the fields of medicines and the like.

The invention provides a medicine for treating acute hepatic failure. The medicine comprises curcumin and extracellular vesicles derived from honey. The invention further provides a preparation method and application of the medicine. According to the invention, the extracellular vesicles are separated from the honey and are proved to have a remarkable anti-inflammatory effect, curcumin is loaded to the extracellular vesicles of the honey, the treatment effect on acute hepatic failure is excellent, and a new effective medicine is provided for clinic.

The current invention relates to isolated Extracellular Vesicles (EVs) wherein said EVs comprise the miRNA markers hsa-miR-125b-5p, hsa-miR-199a-3p, hsa-miR-199b-3p and hsa-miR-16-5p.

The present invention provides a method of recovering an extracellular vesicle from an extracellular vesicle-containing sample. More specifically, the present invention provides a method of recovering the extracellular vesicle that includes separating the extracellular vesicle from the extracellular vesicle-containing sample in the presence of a polymer.

The invention discloses an application of SNF2 protein derived from streptococcus angina extracellular vesicles in gastric cancer prognosis. The chromatin remodeling protein SNF2 derived from S.anginosus EVs can be combined with a transcription factor TEAD1, so that the transcription of the palmitoyl transferase ZDHHC11 is promoted together. Then, the stability of the ZDHHC11 is enhanced by catalyzing palmitoylation of PD-L1, and finally immune escape is induced. In addition, SNF2 also can activate AXL, CTGF, CYR61 and other carcinogenic targets at the downstream of TEAD1, thereby further accelerating the malignant progression of gastric cancer. In an in-vivo experiment, the intragastric administration of the S.anginosus EVs not only promotes the tumor growth of mice, but also significantly inhibits the infiltration of CD8 + T cells. Blocking of ZDHHC11 can effectively reverse immune escape, and has a synergistic effect with an anti-PD-1 therapy, so that the treatment effect is remarkably improved.

The present invention provides extracellular vesicle compositions. Also provided are methods of making an extracellular vesicle loaded scaffold using the extracellular vesicle compositions to increase revascularization. Methods of using the extracellular vesicle compositions and the extracellular vesicle loaded scaffold are provided. The scaffold may increase blood flow and oxygenation of the tissue thereby aiding in treatment of disease and injury.

The present invention provides stabilization of an extracellular vesicle. Specifically, the present invention provides, for example, a method of stabilizing the extracellular vesicle including mixing an extracellular vesicle-containing sample with a saccharide and a chelating agent.

The invention relates to a nasal administration preparation containing extracellular vesicles and acellular matrix hydrogel and a preparation method of the nasal administration preparation, and belongs to the technical field of extracellular vesicles. According to the nasal administration preparation, the nasal administration preparation contains extracellular vesicles, acellular matrix hydrogel and auxiliary materials, and the auxiliary materials contain at least one of a lipophilic solvent, a humectant, a thickening agent and an osmotic pressure regulator. The EVs nasal administration dosage form is prepared, the EVs has the capacity of passing through a blood brain barrier, can be delivered to a brain central nervous system and has high brain administration capacity, the human placenta source ECM forms nanofibers through structural regulation and control, the nanofibers are used as a carrier material of the EVs, long-term storage of the biological activity of the EVs can be achieved, the local treatment time of the EVs is prolonged, and the EVs nasal administration dosage form can be applied to the brain. EVs can be efficiently absorbed in the nasal cavity, and compared with similar products, the effective component acting time is longer.

Several embodiments disclosed herein relate to methods and compositions for treatment of inflammation. In several embodiments, therapeutic nucleic acids enriched in extracellular vesicles from fibroblasts engineered to overexpress TDO2 are provided. In several embodiments, a therapeutically effective amount of the isolated nucleic acid is administered to treat an inflammatory condition. In several embodiments, the inflammation is secondary to tissue damage or an infection.

The invention belongs to the technical field of traditional Chinese medicines, and discloses an immature bitter orange-derived extracellular vesicle-like nanoparticle, which is characterized in that the immature bitter orange-derived extracellular vesicle-like nanoparticle is prepared by the steps of crushing immature bitter orange, filtering, centrifuging and resuspending, the average particle size is 60-120 nm, and the particle size of the immature bitter orange-derived extracellular vesicle-like nanoparticle is 20-30 nm. The extracellular vesicle-like nanoparticles are used for entrapment of at least one of naringin, neohesperidin, naringenin and hesperidin. The extracellular vesicle-like nanoparticles derived from immature bitter oranges are simple in preparation method, have liver targeting and good stability, and can be used for preparing medicines for preventing and / or treating liver injury, depression and breast cancer.

Disclosed in the present invention is a use of royal jelly extracellular vesicles (RJEVs) in the preparation of a pharmaceutical composition for treating wounds in individuals suffering from diabetes, wherein the pharmaceutical composition comprises at least one carrier, and the at least one carrier has the characteristics of adhering to the skin of the individuals.

The invention relates to the technical field of cell separation and extraction, and provides a method for extracting extracellular vesicles from induced sputum. Comprising the following steps: S1, atomizing and collecting induced sputum, picking out sputum plugs, and adding an isotonic phosphate buffer solution which contains 0.1 wt% of drocisteine and 0.1 wt% of tween-20 and has the pH value of 6.0 for dissolving, so as to obtain an induced sputum dissolving solution rich in extracellular vesicles; wherein the dissolving temperature is 37 + / -0.1 DEG C, and digestion is performed for 15 + / -1 min under the condition that the rotating speed of a shaking table is 50 + / -1 rpm; and S2, extracting the extracellular vesicles from the induced sputum dissolving solution through a negative pressure size exclusion chromatography method. According to the invention, the multi-component dissolving agent of the hydroxymethylsteine and the Tween-20 is adopted to promote the dissolving of sputum and protect protein and nucleic acid in extracellular vesicles from being degraded; the negative pressure size exclusion chromatography can accurately control the flow velocity driven by negative pressure, ensures stable migration of extracellular vesicles in a chromatographic column, and avoids vesicle rupture caused by too fast flow velocity or low separation efficiency caused by too slow flow velocity.

The present invention addresses the problem of providing: a porous support which can be obtained by separating extracellular vesicles with high purity according to size and affinity; and a method for obtaining extracellular vesicles using the porous support. A method for producing an extracellular vesicle using the porous support; and a kit for obtaining an extracellular vesicle comprising the porous support. According to the present invention, provided are a porous support, a method for obtaining extracellular vesicles using the porous support, a method for producing extracellular vesicles using the porous support, and a kit for obtaining extracellular vesicles, the porous carrier is a porous carrier which is combined with a substance having affinity for the extracellular vesicles and has an exclusion limit molecular weight of 800-60000kDa, and the porous carrier is used for obtaining the extracellular vesicles.

The present disclosure relates to extracellular vesicles (e.g., exosomes) comprising a bioactive molecule covalently linked to the extracellular vesicles via a cleavable linker and an anchoring moiety, the cleavable linker comprising a cell penetrating peptide. The extracellular vesicles can be used as agents for the prevention or treatment of cancer or other diseases. Also provided herein are methods for producing the extracellular vesicles and methods for treating a disease or condition using the extracellular vesicles.

Provided herein are recombinant tumor-selective viral particles comprising a nucleic acid encoding a recombinant polypeptide for directing extracellular vesicles (EVs) to at least one target cell, the recombinant polypeptide comprising at least one targeting moiety for directing the EVs to the at least one target molecule expressed by the at least one target cell; at least one EV anchor polypeptide; and at least one intravesicular polypeptide. The viral particle may be derived from an oncolytic virus. Recombinant polypeptides for programming EVs to target specific molecules are also provided. Therapeutic EVs for delivering payload polypeptides (and / or cargo molecules) to target cells, e.g., in vaccine or cell-free "CAR-T"-like applications, are also described, along with EVs for recruiting immune cells to target cells in EV-mediated BiTE-like applications. Furthermore, oncolytic viruses may be modified to provide additional therapeutic benefits by infecting tumor cells and administering the programmed EVs.

The invention relates to the technical field of biological medicines, in particular to application of extracellular vesicles of Ackermann muciniphila in preparation of trichina control products. Experiments prove that by supplementing the AKK bacterium extracellular vesicles, the intestinal flora of a mouse can be remarkably improved, the immune balance of a host is regulated, and the pathological change of the intestinal tract of the mouse can be improved. Experimental results show that the AKK bacterium extracellular vesicles have a certain protection effect on trichina infected mice and have the advantages of being efficient, safe, easy to produce on a large scale and the like, and a brand new technical solution is provided for prevention and treatment of trichinosis.

Described are method of producing extracellular vesicles from cells by exposing the cells to near UV light. Compositions containing the extracellular vesicles and methods of using the extracellular vesicles are also described.

Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.